The Journal of Practical Medicine ›› 2021, Vol. 37 ›› Issue (23): 3047-3051.doi: 10.3969/j.issn.1006⁃5725.2021.23.017

• Clinical Research • Previous Articles     Next Articles

Baseline related factors of suboptimal immune responders after antiretrovival therapy in HIV patients dur⁃ ing AIDS

WANG Liyang*,TANG Shi,WEN Ying.    

  1. Department of Gastroenterology,the Sixth People′s Hospital of Shenyang,Shenyang 110001,China

  • Online:2021-12-10 Published:2021-12-10
  • Contact: WEN Ying E⁃mail:wenying666466@163.com

Abstract:

Objective To analyze the baseline related factors of suboptimal immune responders after anti⁃ retroviral therapy(ART)and investigate the association of baseline cytomegalovirus(CMV)of suboptimal immune responders (SIR). Methods The patients who received ART treatment for at least 96 weeks and achieved sustained virologic suppression(HIV RNA < 50 copies/mL)of AIDS patients were included in the study as the research objects. According to the count of CD4+ T at week 96 after ART,the patients were divided into the optimal immune responders(OIR,CD4+ T count ≥ 200 μL)group and SIR group(CD4+ T count < 200 μL). Baseline risk factors of SIR were retrospectively analyzed. Multiple regression analyses were done to assess the correlation of base⁃ line risk factors with SIR. Results 87 patients were included according to the inclusion standard in the study,with 29 in the SIR group with a ratio of 33.3%,and 58 in the OIR group. There were significantly differences in base⁃ line CD4 + T count,baseline CD8 + T count,CMV DNA,Pneumocystis carinii pneumonia,WHO clinical staging CMV infection. By Logistic regression analysis,the age of ≥ 50 years and the count of baseline CD4+ T < 100 /μL were the relevant baseline risk factors for SIR at week 96 after ART. Conclusions The baseline risk factors for SIR at week 96 after ART include AIDS HIV-infected individuals,patient aged ≥ 50 years and baseline CD4 +T count < 100 /μL and baseline CMV infection status is not associated with SIR.

Key words:

human immunodeficiency virus, cytomegalovirus, antiretroviral therapy, suboptimal immune responder